https://mindmedicinelaw.com/briefing/esketamine-dissociation-and-depression-clinical-implications-for-u-s-practice-20260920-43521The Psychedelic Journalen2026-09-20T15:04:21.122706+00:00Esketamine Dissociation and Depression: Clinical Implications for U.S. Practiceesketamine, dissociation, treatment-resistant depression, clinical trials, subjective effects, FDA, psychedelic therapy, risk-benefit assessment, precision psychiatryhttps://mindmedicinelaw.com/briefing/defining-dmt-assisted-therapy-guidance-for-clinical-trials-20260918-43302The Psychedelic Journalen2026-09-19T22:05:24.513109+00:00Defining DMT-Assisted Therapy: Guidance for Clinical Trialsdmt-assisted therapy, complex interventions, clinical trial design, systematic reviews, psychedelic research, regulatory guidance, efficacy assessment, contextual factors, integration therapyhttps://mindmedicinelaw.com/briefing/dmt-assisted-therapy-complex-intervention-framework-urged-20260918-43301The Psychedelic Journalen2026-09-19T22:05:13.570249+00:00DMT-Assisted Therapy: Complex Intervention Framework Urgeddmt-assisted therapy, complex interventions, clinical trial design, systematic reviews, psychedelic research, substance misuse, pharmacological vs non-pharmacological, integration therapy, ceremonial context, evidence synthesishttps://mindmedicinelaw.com/briefing/employment-risk-for-psychedelic-trial-participants-legal-and-ethical-gaps-20260918-43279The Psychedelic Journalen2026-09-19T22:05:01.357483+00:00Employment Risk for Psychedelic Trial Participants: Legal and Ethical Gapspsychedelic clinical trials, employment risk, workplace drug testing, informed consent, legal protections, anti-discrimination policy, trial design, participant recruitment, ethics, federal lawhttps://mindmedicinelaw.com/briefing/hallucinogen-use-surpasses-other-illicit-drugs-in-urban-and-rural-us-20260918-43244The Psychedelic Journalen2026-09-19T22:04:51.576786+00:00Hallucinogen Use Surpasses Other Illicit Drugs in Urban and Rural UShallucinogen use, illicit drugs, urban vs rural, public health, harm reduction, psychedelic research, opioid misuse, drug policy, substance use trendshttps://mindmedicinelaw.com/briefing/employment-risks-in-psychedelic-chronic-pain-trials-u-s-policy-implications-20260918-43280The Psychedelic Journalen2026-09-19T22:04:30.632578+00:00Employment Risks in Psychedelic Chronic Pain Trials: U.S. Policy Implicationspsychedelic clinical trials, chronic pain, employment risks, workplace drug testing, informed consent, trial design, policy implications, participant protection, ethics, u.s. lawhttps://mindmedicinelaw.com/briefing/definium-lsd-trial-and-compass-training-shaping-psychedelic-therapies-in-2026-20260918-43105The Psychedelic Journalen2026-09-18T22:04:34.208998+00:00Definium LSD Trial and Compass Training: Shaping Psychedelic Therapies in 2026definium lsd trial, compass pathways, psilocybin therapist training, psychedelic clinical trials, anxiety treatment research, patient variability, regulatory policy, adverse effects, workforce development, psychedelic medicinehttps://mindmedicinelaw.com/briefing/psilocybin-restores-social-behavior-in-ocd-mouse-model-prefrontal-circuit-insigh-20260917-43247The Psychedelic Journalen2026-09-19T22:04:41.308437+00:00Psilocybin Restores Social Behavior in OCD Mouse Model: Prefrontal Circuit Insightspsilocybin, ocd, sapap3 knockout mice, social cognition, prefrontal cortex, clinical translation, psychedelic research, mechanism of action, sex differences, neuropsychiatric disordershttps://mindmedicinelaw.com/briefing/structure-based-design-of-5-ht2ar-selective-psychedelic-analogs-20260917-43283The Psychedelic Journalen2026-09-19T22:04:11.040380+00:00Structure-Based Design of 5-HT2AR-Selective Psychedelic Analogs5-ht2ar, psychedelic analogs, structure-based drug design, cardiac safety, serotonin receptor selectivity, cryo-em, pharmacophore modeling, clinical development, neuropsychiatric therapeuticshttps://mindmedicinelaw.com/briefing/structural-blueprint-for-safer-5-ht2ar-psychedelic-drugs-20260917-43281The Psychedelic Journalen2026-09-19T22:04:00.010036+00:00Structural Blueprint for Safer 5-HT2AR Psychedelic Drugs5-ht2ar selectivity, 5-ht2br safety, psychedelic drug design, cryo-em structure, cardiac valvulopathy, medicinal chemistry, regulatory risk, serotonergic compounds, clinical developmenthttps://mindmedicinelaw.com/briefing/fda-faces-pressure-to-clarify-psychedelic-drug-standards-in-us-20260917-43200The Psychedelic Journalen2026-09-19T15:04:03.535389+00:00FDA Faces Pressure to Clarify Psychedelic Drug Standards in USfda psychedelic guidance, psychedelic drug regulation, clinical trial standards, patient access psychedelics, mdma psilocybin lsd, policy uncertainty, public health risk, breakthrough therapy designationhttps://mindmedicinelaw.com/briefing/patient-expectations-shape-ketamine-outcomes-in-depression-care-20260916-43448The Psychedelic Journalen2026-09-20T15:04:32.166330+00:00Patient Expectations Shape Ketamine Outcomes in Depression Careketamine, treatment-resistant depression, patient expectations, psychedelic therapy, qualitative research, clinical trial design, subjective experience, psychological context, mental health policyhttps://mindmedicinelaw.com/briefing/optimi-health-s-phase-3-mdma-ptsd-trial-expands-psychedelic-research-in-canada-20260916-43361The Psychedelic Journalen2026-09-19T22:04:21.184628+00:00Optimi Health’s Phase 3 MDMA-PTSD Trial Expands Psychedelic Research in Canadamdma-assisted therapy, ptsd clinical trials, optimi health, health canada, psychedelic research, phase 3 trial, regulatory pathways, maps, canadian drug policyhttps://mindmedicinelaw.com/briefing/fda-s-2026-public-hearing-on-psychedelics-policy-and-research-implications-20260915-43201The Psychedelic Journalen2026-09-19T15:03:50.883650+00:00FDA’s 2026 Public Hearing on Psychedelics: Policy and Research Implicationsfda psychedelics hearing, psychedelics policy, federal regulation, clinical trial design, public health, drug scheduling, stakeholder input, research barriers, rescheduling, psychedelic therapyhttps://mindmedicinelaw.com/briefing/thermodynamic-markers-of-consciousness-sleep-psychedelics-and-anesthesia-20260913-42887The Psychedelic Journalen2026-09-18T22:04:51.282525+00:00Thermodynamic Markers of Consciousness: Sleep, Psychedelics, and Anesthesiaconsciousness markers, thermodynamics of consciousness, psychedelic neuroscience, sleep invariants, anesthesia research, neural biomarkers, information theory brain, clinical trial methodology, energy/information ratio, biomarker validationhttps://mindmedicinelaw.com/briefing/ai-vs-medical-students-divergent-psychedelic-harm-ratings-in-clinical-education-20260912-42890The Psychedelic Journalen2026-09-18T22:05:07.206386+00:00AI vs. Medical Students: Divergent Psychedelic Harm Ratings in Clinical Educationai drug harm assessment, psychedelic safety, chatgpt medical education, drug policy, substance harm perception, medical student training, regulatory implications, evidence-based medicine, clinical decision supporthttps://mindmedicinelaw.com/briefing/biomarker-guided-neuromodulation-for-trd-lessons-for-psychedelic-trials-20260911-42877The Psychedelic Journalen2026-09-18T22:05:21.129661+00:00Biomarker-Guided Neuromodulation for TRD: Lessons for Psychedelic Trialstreatment-resistant depression, biomarkers, machine learning, rTMS, esketamine, precision psychiatry, psychedelic therapy, predictive models, clinical trials, neurophysiology